Our latest article summarises the key changes to be aware of for the upcoming EU HTA, as well as imp...
Read moreWe explore CAR T-cell therapy challenges, regulatory approvals, market growth, pricing models, and a...
Read moreSafety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i...
Read moreWe discuss the 2024 VPAG agreement, how it differs from the previous VPAS and whether this will impa...
Read moreWe examine the effects on patient access, specifically regarding pathways, high value steps, multi-i...
Read moreThis expert article focusses on the new proportionate approach, and the international recognition pr...
Read moreOur experts provide an overview of the five key trends that could shape the pricing and market acces...
Read moreBack in January this year, we summarised the key trends our market access experts believed would dom...
Read moreWe summarise the World Orphan Drug Congress Europe 2023 including keynote and panel sessions on EU H...
Read moreWe outline the challenges pharma companies encounter when launching cell and gene therapies, and ass...
Read more